Kura Oncology, Inc. (KURA) Stock Price & Analysis

Kura Oncology, Inc. (KURA) closed at USD 10.56 on Thursday, October 29, 2026, down 1.49% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 10.72; the Oct 29, 2026 session ranged USD 10.5–10.96 on volume of 1,590,228 shares. Market capitalization is $939.42M, with a 52-week range of USD 7.36–13.9 (NMS). Source: Nexqual, retrieved October 29, 2026 at 22:21 UTC.

Also available as compact Markdown for AI agents: nexqual.com/KURA.md

Key facts (KURA)

• Last four reported quarters (through Jun 30, 2026): revenue $77.2M, net income -$297M (-384.3% margin), free cash flow -$117M (SEC filings).
• Insider open-market sales, last ~7 months: 13 Form 4 filings, $2.7M; 2 not under a Rule 10b5-1 plan ($273K); 0 by opportunistic insiders, 3 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 2 Form 4 filings, $2.4M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.88 on a 1–5 scale) (16 analysts), mean target USD 31.85 (range 15–76).
• Total return with dividends: 1Y +1.1% vs S&P 500 +14.4%; 5Y -35.7% vs S&P 500 +79.1%.
• Next earnings: 2026-11-03, EPS estimate USD -0.81, revenue estimate $23.8M. All companies reporting that day: https://nexqual.com/earnings/2026-11-03
• Dividend: KURA paid no cash dividend in the last five years.
• Short interest: 16.52% of float (as of 2026-10-15), 8.0 days to cover.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KURA)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (KURA)

P/S 12.2x · EV/Sales 5.6x · P/B 19.4x · FCF yield -12.50% · Earnings yield -31.59% · Net cash $509M · EV $430M

Insider sales (SEC Form 4, open-market, last ~7 months) (KURA)

11 of 13 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (KURA)

2 purchases, $2.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (KURA)

Consensus Buy (mean 1.88 on a 1–5 scale), 16 analysts; mean target USD 31.85 (low 15, high 76).

Rating changes, last 120 days:

Total return (dividends reinvested) (KURA)

Dividends (KURA)

KURA paid no cash dividend in the last five years.

Short interest (KURA)

14,319,826 shares sold short, 16.52% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 14,820,592 shares (-3.4%). Days to cover: 8.0 (short shares ÷ average daily volume).

KURA earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

KURA recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

KURA revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

KURA suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 5, 2026.

KURA company outlook (results filed Aug 12, 2026)

• “Combined with $180 million in anticipated collaboration payments from Kyowa Kirin, the Company believes its current cash resources will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.”
• “Such forward-looking statements are current only 6 as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.”

Quoted word-for-word from the SEC 8-K results press release.

KURA analyst estimates and revisions

KURA options: expected move

Options price a move of about ±17.0% (±$1.83) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±2.9% on average.

30-day implied volatility 71.1% vs 48.2% realized over the last 30 trading days. Put/call ratio (volume) 1.86. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 22:21 UTC)

Technical Analysis (KURA)

Nexqual's technical model rates KURA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 22:21 UTC.

Analyst Ratings (KURA)

Wall Street analysts rate KURA "Buy" based on 16 analysts, with a mean price target of USD 31.85 (range USD 15–76), per Nexqual as of October 29, 2026 at 22:21 UTC.

Earnings (KURA)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 22:21 UTC.

Financials & Fundamentals (KURA)

Source: Nexqual, October 29, 2026 at 22:21 UTC.

Financial Health Score (KURA)

Nexqual rates Kura Oncology, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 22:21 UTC.

Ownership (KURA)

Source: Nexqual, October 29, 2026 at 22:21 UTC.

Leadership (KURA)

Kura Oncology, Inc. is led by Troy Edward Wilson, Chairman, CEO & President, per Nexqual as of October 29, 2026 at 22:21 UTC.

Major Backers & Investors (KURA)

Notable institutional backers of Kura Oncology, Inc. include Montanova Capital LLC, BVF Inc., Armistice Capital, LLC, according to Nexqual as of October 29, 2026 at 22:21 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 22:21 UTC.

From Kura Oncology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Partnerships

• In December 2014, we entered into a license agreement with the University of Michigan, which was most recently amended in August 2017, that grants us exclusive worldwide rights under certain patent rights to compounds in our menin-KMT2A program.
• The license agreement with the University of Michigan will terminate upon the last-to-expire patent rights, or may be terminated by us at any time with 90 days written notice of termination or terminated by the University of Michigan upon a bankruptcy by us, payment failure by us that is not cured within 30 days or a material breach of the agreement by us that is not cured within 60 days.

Legal & Regulatory Risks (Item 1A, quoted)

• Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of KOMZIFTI or any other approved products.
• Our marketing approval for KOMZIFTI in the United States for adult patients with relapsed or refractory NPM1-mutated AML is subject to post-approval regulatory requirements and commitments, and we may be subject to penalties, restrictions or withdrawal from the market if we fail to comply with these requirements and commitments or if we experience unanticipated problems with KOMZIFTI.
• We anticipate that our current product candidates and any future product candidates may be used in combination with third-party drugs or biologics, some of which may still be in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.
• Failure by us or our third-party collaborators to develop, validate and obtain regulatory approval for a diagnostic testing platform could harm our drug development strategy and operational results.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:21 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt